<DOC>
	<DOCNO>NCT02614547</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , parallel-group , placebo-controlled study efficacy , safety , pharmacokinetics SAGE-547 Injection adult female subject diagnose severe postpartum depression</brief_summary>
	<brief_title>A Study Evaluate SAGE-547 Patients With Severe Postpartum Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression , Postpartum</mesh_term>
	<criteria>Key Subject either must cease lactate Screening ; still lactate Screening , must already fully permanently wean infant ( ) breastmilk ; still actively breastfeed Screening , must agree cease give breastmilk infant ( ) prior receive study drug . Subject Major Depressive Episode begin earlier third trimester later first 4 week follow delivery , diagnose Structured Clinical Interview DSMIV Axis I Disorders ( SCIDI ) Subject â‰¤ six month postpartum Subject must amenable IV therapy Key Active psychosis Attempted suicide associate index case postpartum depression Medical history seizures Medical history bipolar disorder Note : suicidal ideation exclusion . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>